Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants

Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected billions of individuals and is the cause of the current global coronavirus disease 2019 (COVID-19) pandemic. We previously developed an mRNA vaccine (LVRNA009) based on the S protein of the Wuhan-Hu-1 strain; the phases I...

Full description

Bibliographic Details
Main Authors: Jianglong Li, Qi Liu, Jun Liu, Zihui Fang, Liping Luo, Shuang Li, Yixin Lei, Zhi Li, Jing Jin, Ronglin Xie, Yucai Peng
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Vaccines
Subjects:
SARS-CoV-2 variants
mRNA vaccine
spike protein
neutralizing antibody
Online Access:https://www.mdpi.com/2076-393X/10/11/1807

Internet

https://www.mdpi.com/2076-393X/10/11/1807

Similar Items